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Abstract
Background: We report the case of a patient with treated Stage Ia seminoma who was found to
have an elevated beta human chorionic gonadotrophin (hCG) on routine follow – up. This
instigated restaging and could have lead to commencement of chemotherapy.
Case presentation: The patient was a bodybuilder, and following a negative metastatic work –
up, admitted to injecting exogenous beta hCG. This was done to reduce withdrawal symptoms
from androgen abuse. The patient remains well eight years post diagnosis.
Conclusion: This case highlights the need for surgical oncologists to conduct vigilant screening of
young male patients with a history of testicular germ cell tumours and who may indulge in steroid
abuse.
Background
Testicular cancer accounts for 1% of all male cancers [1],
and while the incidence has doubled in the last twenty
years, the overall 5 – year survival is in the order of 99%.
Among urologists and radiation oncologists, the follow –
up of patients with testicular malignancies requires metic-
ulous screening for distant metastases and careful surveil-
lance with tumour marker measurement. These include
alpha – foetoprotein (AFP) and beta human chorionic
gonadotrophin (hCG), used to supplement clinical and
radiologic evaluation. This case report details only the sec-
ond published case of false positive beta hCG due to exog-
enous hCG administration [2].
Case presentation
A 26 year old man presented to the urology service with a
left testicular swelling. Clinical examination, followed by
testicular ultrasound confirmed the presence of a testicu-
lar tumour. After a negative metastatic work – up, the
patient proceeded to a left inguinal orchidectomy. This
was followed by prophylactic para – aortic nodal irradia-
tion to a total dose of 25 Gray (Gy) in 17 fractions. He
then had a five year period of routine surveillance with
clinical examination, tumour marker evaluation and
annual computed tomographic (CT) scan. After five years
a routine beta hCG was measured at 28.5 mIU/mL (nor-
mal 1.0 – 5.3 mIU/mL) and this raised concern regarding
recurrence of his seminoma. This instigated a complete re
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metastatic work – up. These were all normal.
On further consultation, the patient admitted to self –
administering intramuscular Nandrolone, an anabolic
steroid for the previous one year. He had recently discon-
tinued them and was taking hCG to minimise the side
effects associated with their withdrawal. He discontinued
hCG injections and his beta hCG normalised. He is well
with no evidence of disease three years later.
Discussion
In early stage testicular seminoma the cure rate with
orchidectomy alone is up to 99% in some series. The most
common area for recurrence is in the retroperitoneal and
para – aortic nodes and this, coupled with their radiosen-
sitivity, has led to the practice of adjuvant nodal irradia-
tion in stage I seminoma for over 50 years [3]. The
standard portal in this institution is from the lower border
of the T10 vertebral body to the lower body of the L5 ver-
tebra, encompassing the spinous processes and the ipsilat-
eral renal hilum. The Medical Research Council (MRC)
randomised trial, TE10, compared para – aortic strip irra-
diation (PAS) only with dog – leg field irradiation (DL),
i.e., inclusion of the ipsilateral iliac nodes to a dose of 30
Gy in 478 patients [4]. The relapse rates in both groups
were low with only nine patients relapsing in each group
at 4.5 years median follow – up. During radiation treat-
ment, nausea and vomiting, diarrhoea and, in particular,
leukopenia occurred less often in the PAS arm than in the
DL arm. The later MRC trial, TE 18 [5], assigned 625
patients to either 20 Gy in 10 fractions versus 30 Gy in 15
fractions. It concluded that there were no additional
relapses in those receiving 20 Gy in 10 fractions versus 30
Gy in 15 fractions. Furthermore, it concluded that there
was more lethargy, leucopenia and dyspepsia in the 30 Gy
group.
Human chorionic gonadotrophin (hCG) is a highly spe-
cific and sensitive germ cell tumour marker. It is detecta-
ble in the serum of up to 49% of thise with seminomas at
the time of diagnosis [6]. It is secreted by both seminomas
and non – seminomas and while the alpha subunit is also
found in other human hormones such as luteinising hor-
mone (LH), the beta subunit is specific. A rising hCG can
often precede the development of overt clinical or radio-
logical disease and is generally taken to reflect recurrence.
While most hospital assays measure the beta subunit, this
would not necessarily identify exogenous administration,
as seminomas can secrete the beta subunit, the intact mol-
ecule or both. A number of other malignancies can also
secrete hCG (Table 1) and a false positive result can also
be caused by smoking marijuana [7]. Only one previous
case of a false positive result due to hCG injection has
been previously described in the literature [2].
The illicit use of supraphysiological doses of anabolic ster-
oids (AS) by male athletes has been common practice
since the 1950 's and they are often taken in combination
regimens – a process known as ' stacking '. The use of
drugs such as Nandrolone in clinical practice is at doses of
50 milligrams every 3 weeks, but can be at doses of up to
800 milligrams weekly in bodybuilding and other sports
where they are abused. There are many side effects associ-
ated with their use, including hepatic dysfunction,
increase in total cholesterol and resultant cardiovascular
morbidity, left ventricular hypertrophy, behavioural
changes, thyroid dysfunction and even an increase in the
risk of developing Wilms tumour, prostate adenocarci-
noma and hepatocellular carcinoma. In males, even low
doses of anabolic steroids cause hypogonadotrophic
hypogonadism via inhibition of the production of Lutein-
ising hormone (LH) and Follicle stimulating hormone
(FSH). This can lead to diminished sperm production, tes-
ticular atrophy and gynaecomastia. The extent of the sup-
pression of endogenous testosterone production is
dependent on the strength of steroid used and the dura-
tion of the usage. Therefore, abusers seek to increase the
body's own endogenous testosterone production as
quickly as possible. This is done with hCG, at doses of up
to 15,000 iu every three days. As hCG increases both tes-
tosterone and oestrogen, an antioestrogen such as
Tamoxifen or Clomid may be taken to avoid oestrogen
excess.
Conclusion
This case highlights the problems associated with the
withholding of relevant information regarding medica-
tion by patients from their doctors. An elevated hCG is
often all that is needed to institute chemotherapy. In our
case, this led to a number of unnecessary and costly inves-
tigations. This unusual case teaches a salutory lesson to
both urologists and oncologists and illustrates the need
for full disclosure by patients with seminoma of their
medical history. This could prevent unnecessary investiga-
tions by urologists, radiation oncologists and medical
oncologists involved in their care.
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